Protein Kinase Inhibitors: all 15,280 studies that test it

Page 77 of 153. Open to participants first (2,558), then studies with results posted, then the rest; newest registration first within each.

• Multicenter Trial of ESK981 in Patients With Select Solid TumorsActive, not recruitingNCT05988918Phase 2
• IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal MelanomaActive, not recruitingNCT05987332Phase 2/3
• IN10018 Combination Therapy in Previously-treated Solid TumorsWithdrawnNCT05982522Phase 1/2
• To Evaluate the Effect of Food on the Pharmacokinetics of TQ05105 Tablets in Healthy Adult SubjectsCompletedNCT05982106Phase 1
• A Study of TAK-279 in Adults With or Without Liver DamageCompletedNCT05976321Phase 1
• A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistaminesActive, not recruitingNCT05976243Phase 3
• A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC).TerminatedNCT05975645Phase 1
• Lenvatinib, Pembrolizumab, and Tumor Treating Fields (TTFields) for Second-line Treatment of GlioblastomaWithdrawnNCT05973903Phase 1/2
• REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)Active, not recruitingNCT05973773Phase 3
• Evaluating the Effect of Ursodeoxycholic Acid in Patients With Rheumatoid ArthritisCompletedNCT05973370Phase 2
• A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SKI-G-801 in Patients With Advanced Solid TumorsActive, not recruitingNCT05971862Phase 1
• Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic LeukemiaActive, not recruitingNCT05971251Phase 1
• Baricitinib Versus Azathioprine in Patients With Moderate-to-Severe Atopic DermatitisCompletedNCT05969730Not applicable
• Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment TrialWithdrawnNCT05967286Phase 2
• Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus ErythematosusActive, not recruitingNCT05966480Phase 2
• A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic LeukemiaActive, not recruitingNCT05963074Phase 2
• Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeTerminatedNCT05961839Phase 1
• TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC)Active, not recruitingNCT05955391Phase 2
• POC Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Intermediate, Posterior, or Pan NIUTerminatedNCT05953688Phase 2
• A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell LymphomaActive, not recruitingNCT05951959Phase 2
• Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in CholangiocarcinomaActive, not recruitingNCT05948475Phase 3
• Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent LorlatinibWithdrawnNCT05948462Phase 2
• A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's SyndromeActive, not recruitingNCT05946941Phase 3
• Continuation of Serplulimab Plus Chemotherapy After First Progression in Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma: an Open-label, Randomised Phase II TrialStatus unknownNCT05942573Phase 2
• A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based ChemotherapyActive, not recruitingNCT05941897Phase 2
• A Single-arm, Open-label, Single-center Prospective Study of Fruquintinib Combined With Envafolimab in the Treatment of Advanced or Unresectable Locally Advanced Bone and Soft Tissue SarcomaSuspendedNCT05941325Phase 2
• Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell LymphomaCompletedNCT05940064Phase 2
• Zanubrutinib Treatment in Patients With IgM Monoclonal Gammopathy and Antri-MAG Related PolyneuropathyActive, not recruitingNCT05939037Phase 2
• Drug-Drug Interaction Study With AGMB-129 and Midazolam in Healthy ParticipantsCompletedNCT05937386Phase 1
• Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)TerminatedNCT05935748Phase 2
• Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)CompletedNCT05934526Phase 3
• Safety, Tolerability and Symptomatic Efficacy of the ROCK-Inhibitor Fasudil in Patients With Parkinson's DiseaseCompletedNCT05931575Phase 2
• HMPL-453 Food Effect and PPI Study in Healthy Volunteer StudyCompletedNCT05930119Phase 1
• A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced MelanomaTerminatedNCT05926960Phase 2
• First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKIActive, not recruitingNCT05920135Phase 1/2
• A Phase 1 Study of BMF-500 in Adults With Acute LeukemiaCompletedNCT05918692Phase 1
• A Study to Determine the Effect of Multiple Oral Doses of SLx-2119 in Healthy Male SubjectsCompletedNCT05918627Phase 1
• A Study to Determine the Effect of 500 mg Oral Dose of KD025 in Healthy Male and Post-menopausal Female SubjectsCompletedNCT05918614Phase 1
• A Study to Determine the Effect of Multiple Oral Doses and Regimens of KD025 in Healthy Male and Post-menopausal Female SubjectsCompletedNCT05918588Phase 1
• A Food Effect Study of LP-168 Tablets in Healthy SubjectsCompletedNCT05917964Phase 1
• Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic CholangiocarcinomaStatus unknownNCT05913661Phase 2
• FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform NeurofibromasActive, not recruitingNCT05913037Phase 3
• Efficacy and Safety of Ruxolitinib in Neuromyelitis Optica Spectrum DisordersWithdrawnNCT05909943Phase 1/2
• Efficacy and Safety of Surufatinib Combined With Gemcitabine and Albumin-bound Paclitaxel in the Peri-operative Treatment of Pancreatic CancerCompletedNCT05908747Phase 2
• (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular MelanomaActive, not recruitingNCT05907954Phase 2
• A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X MutationsActive, not recruitingNCT05907304Phase 1
• Phase I Clinical Study of SPH4336 Tablets in the Treatment of Advanced Solid TumorsCompletedNCT05905614Phase 1/2
• Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.WithdrawnNCT05905341Phase 1
• Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 MutationsCompletedNCT05904730Phase 1
• Study on Food Influence and Drug-drug Interaction of HLX208 Tablets in Chinese Healthy SubjectsCompletedNCT05902728Phase 1
• Lenvatinib Treatment in Waiting List of Liver Transplantation After TACE Failure in Patients With Hepatocellular CarcinomaActive, not recruitingNCT05901194Phase 1/2
• The Efficacy and Safety of Corticosteroids in Combination With Ruxolitinib in the Management of Checkpoint Inhibitor PneumoniaCompletedNCT05899725Not applicable
• A Study of Lazertinib (JNJ-73841937) Tablet in Healthy Adult ParticipantsCompletedNCT05896683Phase 1
• A Study to Evaluate the Effect of Cholestyramine on LOXO-783 in Healthy ParticipantsCompletedNCT05894928Phase 1
• A Study of ABM-1310 in Patients With BRAF V600-Mutant Relapsed and Drug Resistant Primary Malignant Brain TumorsTerminatedNCT05892653Phase 1
• A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the BrainActive, not recruitingNCT05892068Phase 2
• A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF TherapyActive, not recruitingNCT05889182Phase 3
• A Study to Assess the Effects of Fluvoxamine on Savolitinib Exposure in Healthy Male SubjectsCompletedNCT05888207Phase 1
• A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGLStatus unknownNCT05883085Phase 2
• Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)CompletedNCT05882734Phase 1/2
• A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung CancerActive, not recruitingNCT05880706Phase 2
• Ritlecitinib in CTCLTerminatedNCT05879458Phase 2
• A Study to Evaluate Efficacy and Safety of Lenvatinib Combined With Tislelizumab in Patients With FHRCCCompletedNCT05877820Phase 2
• The Safety and Efficacy of HAIC+Tislelizumab+Regorafenib in Patients With Colorectal Liver MetastasesStatus unknownNCT05877001Phase 2
• Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving TopotecanActive, not recruitingNCT05874401Phase 4
• A Phase 1 Clinical Study of NXP900 in Subjects With Advanced CancersActive, not recruitingNCT05873686Phase 1
• [14 C] Study on Mass Balance of TY-9591 in Healthy Chinese SubjectsCompletedNCT05871905Phase 1
• [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast CancerActive, not recruitingNCT05870579Phase 1
• Parsaclisib in Patients With Relapsed or Refractory Follicular LymphomaWithdrawnNCT05867030Phase 1
• Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell LymphomaActive, not recruitingNCT05864742Phase 2
• Topical Sirolimus in Chemoprevention of Facial Squamous Cell Carcinomas in Solid Organ Transplant Recipients (SiroSkin)Active, not recruitingNCT05860881Phase 3
• Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following TreatmentActive, not recruitingNCT05859334Phase 2
• REVERSE-Long COVID-19 With Baricitinib StudyWithdrawnNCT05858515Phase 3
• A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus ErythematosusCompletedNCT05856448Phase 2
• To Assess SHR0302 Oral Solutions and Tablets in Healthy Subjects Clinical Studies of Relative BioavailabilityCompletedNCT05856058Phase 1
• Baricitinib in Idiopathic Granulomatous MastitisActive, not recruitingNCT05852171Phase 2
• A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe AsthmaActive, not recruitingNCT05851443Phase 2
• Pembrolizumab Plus Lenvatinib in Previously Treated Classic Kaposi SarcomaWithdrawnNCT05846724Phase 2
• A Study of DZD8586 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (TAI-SHAN1)CompletedNCT05844956Phase 1/2
• Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus ErythematosusActive, not recruitingNCT05843643Phase 3
• STENOVA - A Study to Evaluate Safety, Tolerability, PK and PD of AGMB-129 in Patients With Fibrostenotic Crohn's DiseaseCompletedNCT05843578Phase 2
• Mass Balance Study of [14C]HLX208 in China Healthy SubjectsCompletedNCT05841940Phase 1
• Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)TerminatedNCT05840510Phase 1
• Dasatinib Plus Quercetin for Accelerated Aging in Mental DisordersActive, not recruitingNCT05838560Phase 2
• A Study of the Absorption, Metabolism and Excretion of [14C]XZP-3621 in HumanStatus unknownNCT05836805Phase 1
• Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue SarcomaActive, not recruitingNCT05836571Phase 2
• Effect of Rapamycin in Ovarian AgingActive, not recruitingNCT05836025Phase 2
• Everolimus Aging StudyCompletedNCT05835999Phase 2
• Addition of Everolimus to Standard of Care in Carcinoma GallbladderStatus unknownNCT05833815Phase 2/3
• An Exploratory Clinical Trial to Evaluate and Compare Safety and Pharmacokinetic Characteristics After Administration of the DWJ1439, DWJ1464, DWC202108 or DWC202109 in Healthy Adult VolunteersCompletedNCT05832697Phase 1
• Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors.TerminatedNCT05831995Phase 1
• Fruquintinib Plus Serplulimab as First-Line Therapy for Metastatic Non-Clear Cell Renal Cell CarcinomaActive, not recruitingNCT05831891Phase 2
• Phase Ib / Regorafenib With Conventional Chemotherapy/Newly Diagnosed Patients/ Multimetastatic Ewing SarcomaActive, not recruitingNCT05830084Phase 1
• Anlotinib Capsules in the Treatment for IPF/PF-ILDsActive, not recruitingNCT05828953Phase 2
• A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid TumorsWithdrawnNCT05828303Phase 1
• A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer PatientsWithdrawnNCT05828277Phase 1
• Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate CancerActive, not recruitingNCT05828082Phase 2
• Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene AmplificationsTerminatedNCT05827614Phase 1
• Baricitinib, Methotrexate as Monotherapy or Combination in the Treatment of Rheumatoid Arthritis - an Open Label Randomized Clinical TrialStatus unknownNCT05827497Phase 4
• Phase IIIb Study of Ribociclib + ET in Early Breast CancerActive, not recruitingNCT05827081Phase 3

← Protein Kinase Inhibitors overview